We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

NeoStem Subsidiary PCT Announces Collaboration with ATMI


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NeoStem Subsidiary PCT Announces Collaboration with ATMI"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”) have announced that PCT has entered into a collaboration with ATMI, Inc.

As industry leaders, PCT and ATMI will collaborate on a non-exclusive basis enabling PCT and PCT’s affiliates to offer to their respective clients access to the Integrity® Xpansion™ technology platform from ATMI.

PCT has always been a leader in utilizing the most advanced technology and innovation to pave the path towards commercialization in the regenerative medicine industry.

The Xpansion system will provide bioreactor expansion capability to help clients of PCT and PCT’s affiliates to achieve their development goals by creating and customizing an appropriate development program to suit the needs of each client.

“PCT is pleased to be working with ATMI to offer our clients and potential clients the Xpansion system technology that we believe to be the next generation of two-dimensional technology for adherent cell culture, including stem cells,” said Robert A. Preti, Ph.D., President of PCT and Chief Scientific Officer of NeoStem.

Preti continued, “Along with our investments in Engineering and Innovation, the Xpansion system is an exciting tool that has the potential to help a valuable segment of our client base develop cellular therapeutics in a more cost effective and robust way.”

The Xpansion system is part of the ATMI LifeSciences Integrity family of single-use technologies and has been especially developed by ATMI for large-scale production of stem cells and is based on stacked plates made from the same plastic material as multiple-tray stack systems.

According to ATMI, the Xpansion platform offers many advantages over traditional 2-D cell culture technologies: it operates as a closed system, has a compact footprint, monitors and controls pH and dissolved oxygen (DO), and allows for noninvasive, real-time observation of stem cell growth at multiple locations on the top five to 10 plates.

The Xpansion system has the potential to reduce labor and capital costs and decrease chances of errors and contamination. PCT expects that the Xpansion system will be available for clients in PCT’s East and West Coast facilities.

“This collaboration is mutually beneficial to both PCT and ATMI, as we each have specialized knowledge in our respective spheres of expertise that will ultimately benefit our clients and this emerging industry,” said Senior Vice President and General Manager of ATMI LifeSciences, Mario Philips. “Our collaboration will allow us to share resources and information, and take advantage of new opportunities for business development to the benefit of our customers.”

“NeoStem and its subsidiaries continue to grow and expand the businesses through strategic partnerships, such as with ATMI. We believe these partnerships are critical to remaining at the forefront of innovation through the utilization of new technologies that will enhance efficiencies and cost-effective high quality manufacturing,” said Dr. Robin L. Smith, Chairman and CEO of NeoStem.

Advertisement